The FDA put 4D Molecular Therapeutics’ gene therapy program, 4D-310, on clinical hold, the company announced February 2.
Posts
Through its Alexion subsidiary, AstraZeneca is acquiring Lexington, Mass.-based LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts in genomics and rare diseases.